반응식
[OH:1][CH2:2][CH2:3][N:4]1[CH2:9][CH2:8][NH:7][CH2:6][CH2:5]1.[CH2:10]([O:12][C:13]1[CH:18]=[CH:17][C:16]([S:19](Cl)(=[O:21])=[O:20])=[CH:15][C:14]=1[C:23]1[NH:28][C:27](=[O:29])[N:26]2[C:30]([CH3:36])=[N:31][C:32]([CH2:33][CH2:34][CH3:35])=[C:25]2[N:24]=1)[CH3:11]>ClCCl>[CH2:10]([O:12][C:13]1[CH:18]=[CH:17][C:16]([S:19]([N:7]2[CH2:8][CH2:9][N:4]([CH2:3][CH2:2][OH:1])[CH2:5][CH2:6]2)(=[O:21])=[O:20])=[CH:15][C:14]=1[C:23]1[NH:28][C:27](=[O:29])[N:26]2[C:30]([CH3:36])=[N:31][C:32]([CH2:33][CH2:34][CH3:35])=[C:25]2[N:24]=1)[CH3:11]참가 물질
4
반응물 2
생성물 1
시약·촉매·용매 1
실험 절차
86 mg (0.66 mmol) of hydroxylethylpiperazine are added to a solution of 90 mg (0.22 mmol) of 4-ethoxy-3-(6-methyl-4-oxo-8-propyl-3,4-dihydro-imidazo[1,5-a][1,3,5]triazin-2-yl)-benzenesulfonyl chloride (example VI) in 5 ml of dichloromethane and the reaction mixture is stirred at room temperature for 16 hours. After chromatographic purification (dichloromethane/methanol=95:5), 63 mg (57%) of 2-{2-ethoxy-5-[4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl]-phenyl}-6-methyl-8-propyl-3H-imidazo[1,5-a][1,3,5]triazin-4-one are obtained.
후처리
- customAfter chromatographic purification (dichloromethane/methanol=95:5), 63 mg (57%) of 2-{2-ethoxy-5-[4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl]-phenyl}-6-methyl-8-propyl-3H-imidazo[1,5-a][1,3,5]triazin-4-one
- customare obtained
출처 및 근거
- ORD 기록
- ord-d2b9031c556f4c90a7f67469ddf953db
- 출처 데이터셋
- uspto-grants-2006_08
- 특허 번호
- US07091203B2
연결된 노트
불러오는 중…